95 related articles for article (PubMed ID: 26344684)
1. A new tool in the medical bag shows promise.
Singhal S
J Thorac Cardiovasc Surg; 2015 Oct; 150(4):804-5. PubMed ID: 26344684
[No Abstract] [Full Text] [Related]
2. Vascular endothelial growth factor C complements the ability of positron emission tomography to predict nodal disease in lung cancer.
Farjah F; Madtes DK; Wood DE; Flum DR; Zadworny ME; Waworuntu R; Hwang B; Mulligan MS
J Thorac Cardiovasc Surg; 2015 Oct; 150(4):796-803.e1-2. PubMed ID: 26320776
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of VEGF-C, VEGF-D, and sVEGF-R2 in patients with lung cancer during chemotherapy.
Naumnik W; Izycki T; Swidzińska E; Ossolińiska M; Chyczewska E
Oncol Res; 2007; 16(9):445-51. PubMed ID: 18074680
[TBL] [Abstract][Full Text] [Related]
4. Correlation of serum proteomics patterns of sCD200 (OX-2), sApo-2L (sTRAIL), vitamin-D and homocysteine to quantitative FDG-PET/CT findings in newly diagnosed non-small cell lung cancer.
Bisgnin A; Yalcin AD; Gumuslu S; Kargi B; Kargi A; Savas B; Strauss LG
J BUON; 2013; 18(4):1099-100. PubMed ID: 24344047
[No Abstract] [Full Text] [Related]
5. Serum vascular endothelial growth factors C and D as forecast tools for patients with gallbladder carcinoma.
Liu MC; Jiang L; Hong HJ; Meng ZW; Du Q; Zhou LY; She FF; Chen YL
Tumour Biol; 2015 Aug; 36(8):6305-12. PubMed ID: 25801241
[TBL] [Abstract][Full Text] [Related]
6. Serum vascular endothelial growth factor levels in patients with non-small cell lung cancer.
Demirkazik A; Akbulut H; Ulger AF; Arican A; Ozer I; Acikgoz N; Icli F
Ann Saudi Med; 2004; 24(6):473-5. PubMed ID: 15646168
[No Abstract] [Full Text] [Related]
7. Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients.
Winther-Larsen A; Demuth C; Fledelius J; Madsen AT; Hjorthaug K; Meldgaard P; Sorensen BS
Br J Cancer; 2017 Aug; 117(5):704-709. PubMed ID: 28683468
[TBL] [Abstract][Full Text] [Related]
8. Improved detection of stage I non-small cell lung cancer with a serum-based assay.
Burt BM
J Thorac Cardiovasc Surg; 2015 Mar; 149(3):735-6. PubMed ID: 25598528
[No Abstract] [Full Text] [Related]
9. Chest CT and serum vascular endothelial growth factor-C level to diagnose lymph node metastasis in patients with primary non-small cell lung cancer.
Tamura M; Oda M; Tsunezuka Y; Matsumoto I; Kawakami K; Ohta Y; Watanabe G
Chest; 2004 Aug; 126(2):342-6. PubMed ID: 15302715
[TBL] [Abstract][Full Text] [Related]
10. Is there any correlation between levels of serum ostepontin, CEA, and FDG uptake in lung cancer patients with bone metastasis?
Ayan AK; Erdemci B; Orsal E; Bayraktutan Z; Akpinar E; Topcu A; Turkeli M; Seven B
Rev Esp Med Nucl Imagen Mol; 2016; 35(2):102-6. PubMed ID: 26521996
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor concentration as a predictive marker: ready for primetime?
Kavsak PA; Hirte H; Hotte SJ
Clin Cancer Res; 2010 Feb; 16(4):1341; author reply 1341. PubMed ID: 20145175
[No Abstract] [Full Text] [Related]
12. Serum tumour markers and management of non-small cell lung cancer.
Splinter TA
Lung Cancer; 1995 Oct; 13(2):177-9. PubMed ID: 8581397
[No Abstract] [Full Text] [Related]
13. Serum levels of vascular endothelial growth factor in gastric cancer patients.
Eroğlu A
J Surg Oncol; 2011 Aug; 104(2):222. PubMed ID: 21381039
[No Abstract] [Full Text] [Related]
14. Deciphering Crosstalk Circuits in Non-small Cell Lung Cancers with an Increasing Interval Length of Low Dose CT Screening.
Rosell R; Karachaliou N; Chaib I; Pilotto S; Bria E; Fernández-Martínez JL; Ramirez JL
EBioMedicine; 2015 Aug; 2(8):782-3. PubMed ID: 26425674
[No Abstract] [Full Text] [Related]
15. Serum vascular endothelial growth factor-C level in patients with primary nonsmall cell lung carcinoma: a possible diagnostic tool for lymph node metastasis.
Tamura M; Ohta Y
Cancer; 2003 Sep; 98(6):1217-22. PubMed ID: 12973845
[TBL] [Abstract][Full Text] [Related]
16. Screening for Lung Cancer: What Comes Next?
Peled N; Ilouze M
J Clin Oncol; 2015 Nov; 33(33):3847-8. PubMed ID: 26304887
[No Abstract] [Full Text] [Related]
17. Difference in prognostic values of maximal standardized uptake value on fluorodeoxyglucose-positron emission tomography and cyclooxygenase-2 expression between lung adenocarcinoma and squamous cell carcinoma.
Shimizu K; Maeda A; Yukawa T; Nojima Y; Saisho S; Okita R; Nakata M
World J Surg Oncol; 2014 Nov; 12():343. PubMed ID: 25392182
[TBL] [Abstract][Full Text] [Related]
18. Endothelial growth factor receptor inhibition after radiotherapy.
Giovannini M; Gregorc V; Viganò MG; Spreafico A; Ghio D; Dell'Oca I; Bolognesi A; Villa E
J Thorac Oncol; 2007 Jul; 2(7):662. PubMed ID: 17607125
[No Abstract] [Full Text] [Related]
19. [The prescription of serum tumor markers in a general hospital].
Watine J; Charet JC; Augé MC
Presse Med; 1998 May; 27(18):862, 864. PubMed ID: 9767874
[No Abstract] [Full Text] [Related]
20. Overestimation of the prognostic significance of SUV measurement by positron emission tomography for non-small-cell lung cancer.
Atkins CD
J Clin Oncol; 2005 Sep; 23(27):6799-800; author reply 6800. PubMed ID: 16170191
[No Abstract] [Full Text] [Related]
[Next] [New Search]
